title: From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.
abstract: BACKGROUND
  This study aimed to determine the number of people living with HIV receiving antiretroviral therapy (ART) between 2006 and 2013 in Germany by using the available numbers of antiretroviral drug prescriptions and treatment data from the ClinSurv HIV cohort (CSH).
  
  
  METHODS
  The CSH is a multi-centre, open, long-term observational cohort study with an average number of 10.400 patients in the study period 2006-2013. ART has been documented on average for 86% of those CSH patients and medication history is well documented in the CSH.
  
  
  RESULTS
  The proportion of CSH patients receiving TCMs increased continuously over time (from 85% to 93%; 2006-2013). In contrast, treatment interruptions declined remarkably (from 11% to 2%; 2006-2013). The total number of HIV-infected people with ART experience in Germany increased from 31,500 (95% CI 31,000-32,000) individuals to 54,000 (95% CI 53,000-55,500) over the observation period (including 16.3% without SHI and persons who had interrupted ART). An average increase of approximately 2,900 persons receiving ART was observed annually in Germany.
  
  
  CONCLUSIONS
  A substantial increase in the number of people receiving ART was observed from 2006 to 2013 in Germany.
authors.forename: Daniel
authors.initials: D
authors.lastname: Schmidt
authors.forename: Christian
authors.initials: C
authors.lastname: Kollan
authors.forename: Matthias
authors.initials: M
authors.lastname: Stoll
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Stellbrink
authors.forename: Andreas
authors.initials: A
authors.lastname: Plettenberg
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Frank
authors.initials: F
authors.lastname: Bergmann
authors.forename: Johannes R
authors.initials: JR
authors.lastname: Bogner
authors.forename: Jan
authors.initials: J
authors.lastname: van Lunzen
authors.forename: Jürgen
authors.initials: J
authors.lastname: Rockstroh
authors.forename: Stefan
authors.initials: S
authors.lastname: Esser
authors.forename: Björn-Erik Ole
authors.initials: BE
authors.lastname: Jensen
authors.forename: Heinz-August
authors.initials: HA
authors.lastname: Horst
authors.forename: Carlos
authors.initials: C
authors.lastname: Fritzsche
authors.forename: Andrea
authors.initials: A
authors.lastname: Kühne
authors.forename: Matthias
authors.initials: M
authors.lastname: an der Heiden
authors.forename: Osamah
authors.initials: O
authors.lastname: Hamouda
authors.forename: Barbara
authors.initials: B
authors.lastname: Bartmeyer
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D005858:Germany / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010594:Pharmacies; D015995:Prevalence
chemical_list: D019380:Anti-HIV Agents
references.citation: Lancet. 2003 Jul 5;362(9377):22-9
references.pmid: 12853195
references.citation: PLoS One. 2011;6(12):e27903
references.pmid: 22205931
references.citation: J Int AIDS Soc. 2013;16:18757
references.pmid: 23819908
references.citation: HIV Med. 2014 Feb;15(2):86-97
references.pmid: 24007468
references.citation: AIDS. 2014 Jan 14;28(2):281-3
references.pmid: 24361685
references.citation: BMC Public Health. 2014;14:183
references.pmid: 24555530
references.citation: Health Syst Transit. 2014;16(2):1-296, xxi
references.pmid: 25115137
references.citation: N Engl J Med. 2004 Apr 29;350(18):1850-61
references.pmid: 15115831
references.citation: Clin Infect Dis. 2004 Sep 15;39(6):853-60
references.pmid: 15472819
references.citation: N Engl J Med. 1998 Mar 26;338(13):853-60
references.pmid: 9516219
references.citation: Lancet. 2005 Jul 30-Aug 5;366(9483):378-84
references.pmid: 16054937
references.citation: J Infect Dis. 2006 Jul 1;194(1):11-9
references.pmid: 16741877
references.citation: AIDS. 2006 Aug 22;20(13):1753-61
references.pmid: 16931940
references.citation: AIDS. 2008 Jan 30;22(3):385-93
references.pmid: 18195565
references.citation: Lancet. 2008 Jul 26;372(9635):293-9
references.pmid: 18657708
references.citation: PLoS Med. 2008 Jul 8;5(7):e148
references.pmid: 18613745
references.citation: AIDS. 2008 Oct 1;22(15):1951-60
references.pmid: 18784459
references.citation: AIDS. 2009 Jan 28;23(3):279-91
references.pmid: 19114854
references.citation: Nat Rev Drug Discov. 2009 Jun;8(6):439-40
references.pmid: 19483700
references.citation: Antiviral Res. 2010 Jan;85(1):241-4
references.pmid: 19883695
references.citation: Antiviral Res. 2010 Jan;85(1):39-58
references.pmid: 19887088
references.citation: Antiviral Res. 2010 Jan;85(1):1-18
references.pmid: 20018391
references.citation: AIDS Patient Care STDS. 2010 Feb;24(2):79-85
references.pmid: 20059309
references.citation: HIV Med. 2011 May;12(5):269-78
references.pmid: 20955355
references.citation: PLoS One. 2011;6(9):e23946
references.pmid: 21931626
references.citation: PLoS Med. 2013;10(4):e1001418
references.pmid: 23585736